This weeks CotW is from our recent webinar. This figure demonstrates the results of an analysis focused on identifying biomarkers that are measured together frequently in clinical trials. The goal of the analysis was to identify groups of biomarkers that are linked...
In mid-2015 we worked hard to add a new source of evidence for biomarkers: Laboratory Developed Tests, or LDTs. This was a huge milestone for Amplion. We successfully used our technology to identify biomarkers in a new information source very quickly without...
At Amplion we have a commercial interest in access to high quality clinical information that can inform and contribute to our flagship product, BiomarkerBase. However, we are truly passionate about contributing to higher quality, more personalized, medical...
This week we took a look at FDA-cleared and approved IVDs for oncology, and grouped them based on whether they measure proteins or nucleic acids. Protein-based tests have historically been the dominant type used in the clinic, but this is changing rapidly. Based on...
